Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

SU 11248

Known as: SU 011248, SU011248, SU11248 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

sunitinibsunitinib malate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2009
Highly Cited
2009
Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.
Herein we report that the VEGFR/PDGFR kinase inhibitor sunitinib/SU11248 can accelerate metastatic tumor growth and decrease… Expand
Review
2007
Review
2007
Sunitinib: from rational design to clinical efficacy.
  • L. Chow, S. Eckhardt
  • Journal of clinical oncology : official journal…
  • 2007
    • Corpus ID: 20450892
Sunitinib (SU011248) is an oral small molecular tyrosine kinase inhibitor that exhibits potent antiangiogenic and antitumor… Expand
Highly Cited
2006
Highly Cited
2006
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.
PURPOSE Renal cell carcinoma (RCC) is characterized by loss of von Hippel Lindau tumor suppressor gene activity, resulting in… Expand
Highly Cited
2006
Highly Cited
2006
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.
PURPOSE To establish the safety, pharmacokinetics, and recommended dose of sunitinib, a novel oral multitargeting tyrosine kinase… Expand
Review
2006
Review
2006
Hypothyroidism after Sunitinib Treatment for Patients with Gastrointestinal Stromal Tumors
Context Sunitinib, a tyrosine kinase inhibitor, has recently been approved for the treatment of gastrointestinal stromal tumors… Expand
Review
2005
Review
2005
Role of Tyrosine Kinase Inhibitors in Cancer Therapy
Cancer chemotherapy has been one of the major medical advances in the last few decades. However, the drugs used for this therapy… Expand
  • table 1
  • figure 1
  • table 2
Highly Cited
2005
Highly Cited
2005
A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
PURPOSE A transgenic mouse model has revealed parameters of the angiogenic switch during multistep tumorigenesis of pancreatic… Expand
Highly Cited
2003
Highly Cited
2003
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic…
One challenging aspect in the clinical development of molecularly targeted therapies, which represent a new and promising… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Highly Cited
2003
Highly Cited
2003
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.
FLT3 (fms-related tyrosine kinase/Flk2/Stk-2) is a receptor tyrosine kinase (RTK) primarily expressed on hematopoietic cells. In… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2003
Highly Cited
2003
SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.
The purpose of this study was to evaluate the activity of the indolinone kinase inhibitor SU11248 against the receptor tyrosine… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE